




Corrigendum

The Research Article by Simon Shohet, Noemi Hummel, Shuai Fu, Ian Keyzor, Alasdair MacCulloch, Neil Johnson, Jeff Castelli, Ilona Czarny-Ozga, Tahseen Mozaffar and Howard Thom, “Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data”, which appeared in the October 2024 issue of the *Journal of Comparative Effectiveness Research* (13[10], e240045 [2024]), was published with errors within [Table 1](#) and the Supplementary Materials file, as detailed below.

- [Table 1](#) included incorrect reference numbering, which was unfortunately introduced during the manuscript revision process.
- In the Supplementary Materials file, the figure legends in Supplementary Figures 2 and 3 (pages 46 and 47) were inadvertently cut off.

These errors have now been corrected. These corrections do not affect the overall conclusions of the article.

The authors and editors of the *Journal of Comparative Effectiveness Research* would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.

Table 1. Trial and patient baseline characteristics of included trials.

Trial name	NCT	Trial design	Follow-up time (weeks)	Population	Intervention	n	Age (years), mean (SD)	Male (%)	ERT duration in years, mean (SD)	6MWD in meters, mean (SD)	FVC (predicted [%]), mean (SD)	Ref.
NEO-1/-EXT	NCT01898364/ NCT02032524	Phase I/II, single arm	312	ERT-N	Aval	10	44.8 (20.3)	30.0	0.0 (0.0)	449.2 (118.4)	69.2 (19.3)	[17,55]
				ERT-E		14	46.7 (14.1)	64.3	4.0 (2.0) [†]	440.4 (141.0)	77.3 (16.5)	
COMET	NCT02782741	Phase III RCT	49	ERT-N	Aval	51	46.0 (14.5)	52.9	0.0 (0.0)	399.3 (110.9)	62.5 (14.4)	[12]
					Alglu	49	50.3 (13.7)	51.0	0.0 (0.0)	378.1 (116.2)	61.6 (12.4)	
COMET OLE	NCT02782741	Phase III OLE	96 [‡]	ERT-E [‡]	Aval	44	50.7 (13.9)	54.5	0.9 (0) [‡]	384.7 (139.6)	61.5 (13.5)	[49,56]
ATB200-02	NCT02675465	Phase I/II, single arm	208	ERT-E	Cipa+mig	17	46.4 (11.7) [§]	64.7	7.0 (1.6) [¶]	393.5 (119.7)	57.1 (17.9)	[48]
				ERT-N	Cipa+mig	6	47.2 (12.0) [#]	16.7	0.0 (0.0)	396.0 (75.2)	57.2 (20.8)	
PROPEL	NCT03729362	Phase III RCT	52	ERT-E	Cipa+mig	65	48.1 (12.6) ^{††}	43.1 ^{††}	7.5 (3.4) ^{††}	346.9 (110.2)	67.9 (19.1)	[2]
				ERT-N		20	46.0 (15.3) ^{††}	40.0 ^{††}	0.0 (0.0)	393.6 (112.4)	80.2 (18.7)	
				ERT-E	Alglu ^{‡‡}	30	45.9 (13.5) ^{††}	46.7 ^{††}	7.1 (3.6) ^{††}	334.6 (114.0)	67.5 (21.0)	
				ERT-N		7	43.0 (13.5) ^{††}	71.4 ^{††}	0.0 (0.0)	420.9 (135.7)	79.1 (22.6)	
PROPEL OLE	NCT04138277	Phase III OLE	52	ERT-E	Cipa+mig	37	46.0 (12.7) ^{§§}	51.4	6.7 (4.3) ^{††}	359.7 (137.4) ^{††}	62.8 (20.5) ^{††}	[50,57]

[†]This was derived from the range of 0.9 to 7.9 years provided in Dimachkie *et al.* 2022 [18], using formulas from Wan *et al.* 2014 [56] and assuming a median of $(7.9-0.9)/2 = 3.5$.

[‡]Patients who switched from alglu to aval after the double-blinded primary analysis period in COMET were re-baselined at Week 49, thus, those patients were followed for 96 weeks and considered ERT experienced with a previous ERT duration of the length of the double-blinded primary analysis period (i.e., 49 weeks = 0.9 years).

[§]This was derived as follows: Median and range of Cohort 1 and 4 provided by Mozaffar *et al.* 2023 [17] were converted to mean and SD using formulas from Wan *et al.* 2014 [56]. Then, a weighted mean and pooled SD was calculated to obtain mean and SD of the pooled Cohort 1 and 4.

[¶]A weighted mean and pooled SD was calculated from mean and standard deviation values for Cohort 1 and 4 provided by Mozaffar *et al.* 2023 [17] to obtain mean and SD of the pooled Cohort 1 and 4.

[#]This was derived as follows: Median and range provided in Schoser *et al.* 2022 [57] were converted to mean and SD using formulas from Wan *et al.* 2014 [56].

^{††}From individual patient-level data.

^{‡‡}Excluding one patient who deliberately underperformed on baseline assessments to meet inclusion criteria as described in Schoser *et al.* 2021 [2].

^{§§}This was derived as follows: Median and range were converted to mean and SD using formulas from Wan *et al.* 2014 [56].

6MWD: 6-minute walk distance; Alglu: Alglucosidase alfa; Aval: Avalglucosidase alfa; Cipa+mig: Cipaglucosidase alfa plus miglustat; ERT: Enzyme replacement therapy; ERT-E: ERT experienced; ERT-N: ERT naïve; FVC: Forced vital capacity; OLE: Open-label extension; RCT: Randomized controlled trial; SD: Standard deviation.